Neovacs S.AのIPO年
Neovacs S.AのIPO年は何ですか。
Neovacs S.A.のIPO年は2010です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
EURONEXTのセクタHealth CareにおけるIPO年の企業と比べるNeovacs S.A
Neovacs S.Aは何をしますか。
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Neovacs S.Aと類似のipo年
- ChigoのIPO年は2009です。
- Jade Road InvestmentsのIPO年は2009です。
- Equity MetalsのIPO年は2009です。
- Kerr MinesのIPO年は2009です。
- China e-Wallet PaymentのIPO年は2009です。
- SQS India BFSIのIPO年は2009です。
- Neovacs S.AのIPO年は2010です。
- Broken Hill ProspectingのIPO年は2011です。
- Apollo Global Management IncのIPO年は2011です。
- Hipo ResourcesのIPO年は2011です。
- Cogra 48 SAのIPO年は2011です。
- New Mountain Finance CorpのIPO年は2011です。
- Marfrig Global Foods SAのIPO年は2011です。